Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 7 | 2018 | 173 | 1.040 |
Why?
|
| Bone Marrow | 2 | 2018 | 60 | 0.460 |
Why?
|
| Lysophospholipase | 1 | 2012 | 5 | 0.440 |
Why?
|
| Glycoproteins | 1 | 2012 | 34 | 0.430 |
Why?
|
| Anthracyclines | 3 | 2014 | 51 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 401 | 0.320 |
Why?
|
| Ventricular Function, Left | 3 | 2017 | 195 | 0.270 |
Why?
|
| Heart Ventricles | 2 | 2017 | 107 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2017 | 136 | 0.260 |
Why?
|
| Stroke Volume | 3 | 2017 | 279 | 0.250 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 28 | 0.250 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2014 | 62 | 0.230 |
Why?
|
| Geriatric Assessment | 3 | 2016 | 355 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 546 | 0.190 |
Why?
|
| Sulfides | 2 | 2018 | 24 | 0.170 |
Why?
|
| Caprylates | 2 | 2018 | 25 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2015 | 118 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 666 | 0.150 |
Why?
|
| Aged | 10 | 2018 | 9492 | 0.150 |
Why?
|
| Cardiac Volume | 1 | 2017 | 11 | 0.150 |
Why?
|
| Leukemia | 2 | 2014 | 36 | 0.140 |
Why?
|
| Depression | 2 | 2016 | 382 | 0.140 |
Why?
|
| Biopsy | 2 | 2018 | 241 | 0.140 |
Why?
|
| Female | 12 | 2018 | 18173 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 240 | 0.130 |
Why?
|
| Cognition | 2 | 2016 | 526 | 0.130 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 10 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 83 | 0.130 |
Why?
|
| Prospective Studies | 6 | 2017 | 2021 | 0.130 |
Why?
|
| Middle Aged | 10 | 2018 | 10834 | 0.120 |
Why?
|
| Azacitidine | 1 | 2013 | 28 | 0.120 |
Why?
|
| Lymphoma | 1 | 2013 | 36 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 196 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2013 | 130 | 0.110 |
Why?
|
| Crystallization | 1 | 2012 | 16 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1219 | 0.100 |
Why?
|
| Humans | 12 | 2018 | 29123 | 0.100 |
Why?
|
| Neoplasms | 1 | 2017 | 611 | 0.100 |
Why?
|
| Male | 10 | 2018 | 17815 | 0.090 |
Why?
|
| Aorta | 1 | 2009 | 103 | 0.090 |
Why?
|
| Hospitalization | 1 | 2011 | 417 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3101 | 0.080 |
Why?
|
| Adult | 6 | 2018 | 8426 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 787 | 0.070 |
Why?
|
| Mitoxantrone | 2 | 2018 | 17 | 0.070 |
Why?
|
| Comorbidity | 3 | 2013 | 540 | 0.070 |
Why?
|
| Cytarabine | 2 | 2018 | 52 | 0.070 |
Why?
|
| Recurrence | 2 | 2018 | 235 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2015 | 3719 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1017 | 0.070 |
Why?
|
| Time Factors | 3 | 2017 | 2001 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 436 | 0.060 |
Why?
|
| Mitochondria | 2 | 2018 | 174 | 0.060 |
Why?
|
| Remission Induction | 2 | 2015 | 78 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 2402 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 246 | 0.060 |
Why?
|
| Cell Respiration | 1 | 2018 | 21 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 40 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 90 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 138 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 90 | 0.040 |
Why?
|
| Cell Line | 1 | 2018 | 450 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 64 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2015 | 3112 | 0.040 |
Why?
|
| Physical Examination | 1 | 2016 | 82 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 104 | 0.030 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 168 | 0.030 |
Why?
|
| Risk Factors | 2 | 2013 | 3537 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 113 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 187 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 145 | 0.030 |
Why?
|
| Edema, Cardiac | 1 | 2014 | 13 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 440 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 10 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 58 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 17 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 172 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 88 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 57 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 59 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 141 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 721 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 681 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 2370 | 0.030 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2109 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 709 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 637 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 795 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 263 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 310 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 211 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1108 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 871 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1362 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 816 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 859 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1688 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 1423 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 7299 | 0.020 |
Why?
|